Comparative Pharmacology
Head-to-head clinical analysis: CEFIXIME versus TAZICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIXIME versus TAZICEF.
CEFIXIME vs TAZICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefixime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3, leading to cell lysis and death.
400 mg orally once daily or 200 mg orally every 12 hours for 7–14 days; uncomplicated gonorrhea: 400 mg orally as a single dose
2 g intravenously every 8 hours for serious infections; 1 g intravenously every 8 hours for uncomplicated infections.
None Documented
None Documented
Clinical Note
moderateCefixime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefixime."
Clinical Note
moderateCefixime + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefixime."
Clinical Note
moderateWarfarin + Cefixime
"Warfarin may increase the anticoagulant activities of Cefixime."
Clinical Note
moderatePhenprocoumon + Cefixime
Terminal elimination half-life is 3-4 hours in patients with normal renal function; extends to 11-15 hours in moderate renal impairment (CrCl 20-40 mL/min) and up to 20 hours in severe impairment.
2 hours (prolonged to 4-12 hours in renal impairment; anuria: 20-30 hours).
Renal excretion of unchanged drug accounts for 50-60% of elimination; biliary/fecal elimination accounts for 10-20%.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefixime."